C olorectal cancer (CRC) screening guidelines recommend a 10-year interval if there was no neoplasia detected at a high-quality baseline screening colonoscopy. [1] [2] [3] This recommendation is based on the natural history of colorectal neoplasia, randomized controlled trials of endoscopic screening with sigmoidoscopy, [4] [5] [6] and casecontrol and cohort studies of colonoscopy. [7] [8] [9] [10] [11] [12] [13] [14] All of these data suggest that endoscopic screening has a durable reduction in CRC incidence and mortality of at least 10 years. Individuals with first-degree relatives who had CRC before age 60 years are advised to have follow-up at 5 years after a negative baseline examination.
Many patients have follow-up examinations earlier than 10 years, 15, 16 despite a negative baseline colonoscopy. In a study of utilization of colonoscopy in Medicare beneficiaries, 30% of individuals had a second colonoscopy within 5 years after a negative baseline examination. 16 In the Prostate, Lung, Colorectal, and Ovarian Cancer screening trial, >25% of individuals with no neoplasia at baseline colonoscopy had repeat colonoscopy within 5 years. 15 The reasons for most early examinations are unknown. In some cases, the baseline examination might have been incomplete or compromised by inadequate bowel preparation, in other cases, new symptoms might have resulted in a colonoscopy. Another factor driving early colonoscopy is concerns about development of interval cancer before 10 years.
The outcomes of patients who have no neoplasia found at screening colonoscopy are uncertain. There are several prospective studies that have followed cohorts for 5 years after negative screening colonoscopy to determine rates of advanced neoplasia (defined as tubular adenoma >10 mm, or adenoma with villous histology, high-grade dysplasia, or cancer). The rates of advanced neoplasia at 5 years ranges from 1.4% to 4.4%, [17] [18] [19] [20] [21] [22] which are lower than rates found in baseline average-risk screening. 23 The purpose of this study was to determine why patients with negative colonoscopy have early follow-up examinations at intervals <10 years and their endoscopic outcomes in diverse practice settings. The study cohort was obtained from endoscopy practices that participate in the Clinical Outcomes Research Initiative (CORI), which was established in 1995 to study endoscopy in practice settings throughout the United States. Participating endoscopists use a computerized report generator to produce their reports, and data files are electronically transmitted to a central data repository. Subjects who received screening exams from 2000-2006 (average-risk, family history of CRC, positive fecal occult blood test [FOBT] , or positive sigmoidoscopy) were identified. Those who had no polyps or tumors and had a follow-up examination within 10 years were included in this analysis. Our primary aims were to determine the demographic characteristics of these patients, completeness of the baseline examination, indication for the follow-up examination, and a key endoscopic outcome (rate of polyp [s] >9 mm) of the follow-up examination. Our hypotheses, based on patients with follow-up in our consortium, were that patients who have follow-up in <10 years after an adequate index examination will have a low rate of polyp(s) >9mm, relative to average-risk screening and patients who have examinations within the first year are more likely to have an incomplete baseline examination, due to bowel preparation or other factors.
Methods

Clinical Outcomes Research Initiative
This project was developed in 1995 with the goal of creating a consortium of clinical practice settings to determine utilization and outcomes of endoscopic procedures. Endoscopists use a structured computerized endoscopic report generator to produce endoscopic reports. The data that are transmitted from the local site to the National Endoscopic Database do not contain most patient or provider identifiers and qualify as a Limited Data Set under 45 CFR Section 164.514(e) (2) . After completion of qualitycontrol checks, data from all sites are merged in the data repository for analysis. Procedure counts are monitored on a weekly basis for atypical activity. The repository is checked for anomalies on a daily basis. Any unusual activity prompts follow-up contact by CORI staff. During the study period, the practice sites contributing colonoscopy reports include private practices and endoscopy centers (82.7%), academic centers (8.2%), and Veterans Affairs/Military medical centers (9.1%). CORI was given approval by the Institutional Review Board of the Oregon Health and Science University (eIRB #7331) in October 2011. This specific study utilized a limited dataset and was therefore exempt from further Institutional Review Board review.
Patients
We included all complete colonoscopy reports from 2000 to 2006 in patients undergoing screening examinations without any other indication for colonoscopy. We excluded reports in patients younger than 18 years old. Screening examinations were defined as average-risk, family history of CRC, positive FOBT or positive sigmoidoscopy in the absence of any gastrointestinal (GI) symptoms. Patients who had no polyps or tumors of any kind represent the study cohort. Among these patients, we followed the outcomes of patients who had 1 or more colonoscopy examinations documented in CORI during the follow-up period until 2012. Patients are stratified by interval for the first follow-up examination. Characteristics of the baseline examination, patient demographics, practice site, and indication for the follow-up examination were analyzed.
Outcomes Measurement
There are many possible important outcomes of colonoscopy. For this analysis, we have focused on neoplasia, which would be an important outcome of screening examinations. In nonscreening procedures, other outcomes can be even more important. In this structured database, endoscopists are asked to provide detailed descriptors of every polyp, including size, location, morphology (pedunculated, sessile, or flat) and method of removal. The determination of neoplasia in a polyp requires the addition of histopathology results, which arrive days after the endoscopy. We receive pathology results in 20% of the endoscopy reports, which are a representative sample of the entire cohort in terms of patient demographics and procedure indications.
Our key end point was the finding of 1 or more polyps sized >9 mm or described as a suspected malignant tumor, hereafter termed large polyp. This end point is a surrogate for advanced neoplasia (defined as tubular adenoma 10 mm adenoma with villous histology or high-grade dysplasia and cancer). Our previous analysis of 13,992 screening examinations with histopathology demonstrated that this surrogate was robust. 24 In this analysis, 4.8% of large polyps (>9 mm) did not have advanced histology, and 2.9% of small polyps (1-9 mm) did have advanced histology, and would be misclassified with our surrogate end point. Most of the large polyps without advanced histology were classified as "hyperplastic." Today, we would likely refer to these polyps as serrated lesions, with follow-up management similar to high-risk adenomas. 3 The lesions that are most likely misclassified as nonadvanced in the current analysis are 2.9% of small polyps with advanced histologic features, most of which are 6-9 mm in size. The incidence of these lesions is included in this report.
Analysis
Categorical data are presented as proportions and 95% confidence intervals. Comparisons of categorical data were performed using Pearson's c 2 , and continuous variables were compared using analysis of variance. All tests were 2-sided, and a P value of <.05 was considered statistically significant. All analyses were performed using SAS software v 9.2 (SAS Institute, Inc., Cary, NC). Table 1 . The cohort receiving repeat examinations in the first 5 years was somewhat older than those receiving follow-up in the second 5 years. There was a female predominance after the first year. The baseline examination was compromised by either poor preparation or incomplete examination in 15.5% of patients who had a follow-up examination in <10 years. For comparison, the rate of compromised examinations in the entire cohort with no polyps at baseline (n ¼ 147,375) was 7.3%; the rate of compromised examinations among all patients receiving screening colonoscopy (n ¼ 264,184) was 6.3%.
Results
The indications for the repeat procedures, stratified by interval are shown in a second examination in <10 years, 20.2% were averagerisk without GI symptoms.
In all, 1806 patients (10.3%) had follow-up in <1 year after the baseline colonoscopy. In 73.4% (n ¼ 1,325) of cases, the baseline examination was either incomplete or had poor/compromised bowel preparation. They were more likely to be male and had a mean age of 60.7 years. We compared the demographics of the baseline colonoscopy cohort (n ¼ 264,184) and the 1806 individuals receiving follow-up examination in <1 year (Table 1) . Black patients accounted for 10.1% of the early examinations (compared with 5.9% in the baseline cohort) and Hispanic patients accounted for 13.2% of the early examinations (compared with 5.5% in the baseline cohort).
Among the 1806 patients with negative baseline colonoscopy who had repeat examination in <1 year, 6.5% had large polyp(s) ( Table 3 ). This rate is similar to the prevalence of large polyps among all patients receiving averagerisk screening colonoscopy (6.4% of 158,844 subjects not in our study; P ¼ .89).
There were 15,719 patients who had follow-up colonoscopy between 1 and 10 years after a negative baseline colonoscopy; the incidence of large polyp(s) was 3.1% (95% confidence interval: 2.7-3.5) in years 1 to <5 and 3.7% (95% confidence interval: 3.3-4.1) in years 5 up to 10, which was significantly lower than the 1-year cohort (P < .0001) ( Table 3 ). The incidence of newly discovered proximal large polyps increased with longer duration of follow-up (Table 3 ) from 55% in the first 2 years to 68% in the last 5 years. The proportion of examinations where the most advanced polyp finding was a small polyp (<6 mm) was higher in years 5-10 compared with year 1 to <5 years (21.7% vs 16.9%; P < .0001).
The impact of a compromised baseline examination was assessed during the entire study period (within 10 years of baseline colonoscopy) by comparing all individuals who had compromised baseline examinations with those who had a complete examination (Table 4) . Patients with compromised examinations were slightly older and more likely to be male. Data were classified based on size of largest polyp. Incidence of largest polyp(s) >9 mm (5.4% vs 3.4%; P < .0001) and largest polyp(s) 6-9 mm in diameter (6.6% vs 5.5%; P ¼ .030) was higher in patients with compromised baseline examinations. The incidence of polyps over time (stratified by size of largest polyp) is shown in Figure 2 . Table 5 summarizes the outcomes of follow-up examination based on the procedure indication for the follow-up examination, stratified by interval from baseline colonoscopy. These data show that across each procedure indication, the highest yield of large polyps is in the period <1 year, when inadequate examinations accounted for nearly 75% of patients. The rate of polyp(s) >9 mm after a positive FOBT was only 2.2% in years 1 to <5, and 4.0% in year 5 to <10 after a baseline negative colonoscopy.
Discussion
We studied a unique cohort that had a negative baseline colonoscopy and had follow-up colonoscopy documented in the CORI database. The ideal study would have followed all patients prospectively to determine actual rates of interval colonoscopy. Therefore, this analysis provides only a snapshot of those patients who had follow-up colonoscopy within the CORI network, and does not include the rates of interval colonoscopy. To determine if our cohort was representative of individuals receiving colonoscopy screening examinations, we examined the endoscopic outcomes of the entire cohort of individuals who received average-risk screening at baseline. Among 158,884 individuals undergoing screening that were not included in our study, 10,165 (6.4%) had 1 or more polyps >9 mm. This finding is consistent with rates of advanced neoplasia from other large screening trials. 23 There were 17,525 patients with a negative baseline examination (11.9%) who had repeat colonoscopy in <10 years within the CORI network. Among these subjects, 10.3% had the examination in <1 year. We found that 73.4% of these patients with 1-year examinations had compromised baseline examinations, either due to poor preparation (57.9%) and/or the cecum was not reached (57.1%). The prevalence of large polyp(s) was 6.5% in this group, which is similar to our baseline screening population and other studies. 23 These data highlight several key points. Poor quality bowel preparation, which obscures visualization of the colon, can be associated with missed lesions at the baseline colonoscopy. 25, 26 Current quality indicators for colonoscopy call for monitoring bowel preparation quality, 27, 28 with the goal of achieving preparation that is adequate for detection of lesions >5 mm in 95% of examinations. There is now substantial evidence 29 that splitting the dose of bowel preparation results in better quality and this practice is strongly encouraged by expert panels. 3 The current data provide additional evidence of the importance of the quality of the baseline colonoscopy, and benefits of early re-examination if the baseline examination is compromised.
Among patients with examinations at 1 to 5 years after baseline, the most common reasons for early repeat examinations were family history (30.1%) and GI bleeding or anemia (31.2%), and other symptoms (11.8%). Most guidelines recommend a 5-year interval for screening of individuals with a family history of CRC if the index family member was <60 years, 3 unless they have a hereditary syndrome associated with CRC, such as Lynch syndrome or familial adenomatous polyposis. The evaluation of symptoms such as bleeding or interval fecal blood test or changes in bowel habits after a negative colonoscopy has never been carefully studied.
The incidence of large polyps in years 1 to 5 after a negative baseline colonoscopy is 3.1%, less than half the rate found at average-risk baseline screening (6.4%). There may be other benefits of repeating colonoscopy for evaluation of symptoms that were not measured. Given the low rate of large polyps, additional study is needed to determine if there is any significant benefit to repeating colonoscopy early after a high-quality negative baseline examination. We did not find that family history of CRC was a predictor of increased risk in years 1 up to 5 or 5 to 10 after baseline negative colonoscopy. We do not know what proportion of patients had a first-degree relative <60 years old, for whom screening intervals are recommended at 5 years. Additional study is needed to clarify if this group would benefit from early colonoscopy.
These data demonstrate the lack of effectiveness of repeating FOBT in <5 years after a negative colonoscopy. At baseline colonoscopy, individuals with a positive FOBT have a 2-fold increased prevalence of polyps >9 mm compared with individuals undergoing average-risk screening colonoscopy. We find that after a negative colonoscopy, the incidence of large polyps associated with a positive FOBT in years 1-4.9 years is only 2.2%. The role of FOBT in years 5-10 after a negative colonoscopy is also questionable. We found that 4.0% of such patients had incident large polyps, which is lower than the prevalence of large polyps found at baseline screening colonoscopy. These data reinforce the recommendation to avoid using FOBT after patients have had a negative baseline screening colonoscopy.
Current guidelines recommend a 10-year interval before repeating examinations after a negative baseline colonoscopy in average-risk individuals. Earlier cohort and casecontrol studies have found that colonoscopy screening can have a protective effect 10 years. 9, 11, 13, 14 Two of these studies suggest that the protective effect increases after the first 2 years of follow-up. 11, 13 We suspect that significant neoplasia discovered in the first years after baseline colonoscopy likely represent lesions missed at the baseline examination. After the first year, we and others find low rates of large polyps after a negative baseline, confirming the likelihood that negative colonoscopy, performed with high quality, is associated with a low risk of developing advanced neoplasia during the next 10 years. We observed a trend in the relationship of incidence of proximal large polyps and timing of the interval examination. In the first 2 years after the baseline colonoscopy, 55% of large polyps were found in the proximal colon, and in the later years (5-10 years), 68% of the large polyps were proximal. These data support the hypothesis that proximal lesions are more likely to be missed at baseline colonoscopy, a finding consistent with other studies, which raise questions about the protective effect of colonoscopy in the proximal colon.
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Strengths and Limitations
An important strength of our study is the inclusion of diverse practice sites throughout the United States, which are representative of endoscopic practices in this country. 30 However, endoscopists who are comfortable sharing data from their practice might differ in important ways from those who will not share data or do not use electronic records to monitor quality in their practice. This potential bias could influence the frequency of repeat examinations or reasons for repeat examinations. We report on 10% of patients with negative baseline colonoscopy who had follow-up documented in CORI. It is likely that other patients had follow-up colonoscopies outside of CORI sites and were not captured. Therefore, our follow-up is incomplete. Despite this limitation, this is the largest cohort with documented colonoscopy follow-up after negative baseline examinations. Our follow-up was <10 years in patients who had colonoscopy after 2002. Nevertheless, our cutoff date captured follow-up examinations within 5 years of the baseline colonoscopy for all subjects. The surrogate end point of polyp(s) >9 mm has been shown to correlate well with rates of advanced neoplasia, but some individuals would be misclassified with this end point.
Our analysis focused on a cohort of community-based patients who had negative index screening colonoscopy and had follow-up colonoscopy in <10 years. There are several key findings. Ten percent of these patients had follow-up at <1 year after the baseline examination, most often because of a compromised baseline examination. The yield of large polyps in patients with compromised examinations performed at <1 year was similar to the prevalence at index screening examinations. These data support the need for repeat examination after a compromised index colonoscopy. 3, 25 Overall, the index screening colon examination was compromised in 16,650 of 264,284 patients receiving screening examinations (6.3%), primarily due to poor bowel preparation. If most of these patients have a follow-up examination within 6-12 months, they represent a significant cost burden. To reduce this burden, bowel preparation quality should be monitored as a quality indicator, 27, 28 and split-dose preparations should be universally used. 29 Figure 2 . Incidence of polyps found at follow-up colonoscopy examination, stratified by size of largest polyp and time interval from baseline negative colonoscopy.
We find that if the baseline examination was not compromised, the incidence of significant findings at a 1-to 5-year interval is low, regardless of indication. In particular, our results suggest little benefit of screening with FOBT in the first 5 years after a baseline negative colonoscopy. In other cases, there might be other unmeasured benefits of colonoscopy that should be further evaluated. Finally, these data provide support for the durable protective effect of a negative colonoscopy, provided the baseline examination was adequate. 
